Australian cell therapy company Chimeric Therapeutics (ASX:CHM) has announced that the first patient enrolled in the first-in-human trial of CHM CDH17 has been dosed.
The Phase 1/2 trial is a two-stage study designed to determine a recommended Phase 2 dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumours.
"Treating our first patient is a key milestone for Chimeric as we work to advance new medicines to improve the lives of patients living with cancer." said Dr Rebecca McQualter, the chief operating officer of Chimeric.
Executive Chairman Paul Hopper said, "This is a great moment for patients and the culmination of years of hard work by the Chimeric team."
The Phase 1 portion of this study is expected to enrol 15 patients and lead to dose selection and expansion with indication-specific Phase 2 cohorts.
CHM CDH17 is a third-generation, novel CAR-T cell therapy that targets CDH17, a cancer target associated with poor prognosis and metastasis in the most common gastrointestinal tumours.
